Hot Products
| Catalog No. | Information |
| CFN00231 | Tigloidine Tigloidine hydrobromide, a naturally occuring analogue of atropine, could be as a substitute for atropine in the treatment of parkinsonism. |
| CFN96618 | Tigloylgomisin H Tigloylgomisin H represents a potential liver cancer prevention agent, it can significantly induce quinone reductase (QR) activity in Hepa1c1c7 mouse hepatocarcinoma cells, it functions as a novel monofunctional inducer that specifically upregulates phase II enzymes through the Nrf2-ARE pathway. |
| CFN98501 | Tigogenin Tigogenin is one of steroidal sapogenins which is widely used for synthesizing steroid drugs. It might have protective effect on bone and be helpful in preventing the development of osteoporosis.Tigogenin induces apoptosis, associated with overexpression of COX-2 correlated with overproduction of endogenous PGE2. Tigogenin inhibited of PPARgamma and via p38 MAPK pathway. |
| CFN92764 | Tilianin Tilianin has anti-inflammatory, antiatherogenic, antihypertensive and vasorelaxant activities, mediates relaxation and antihypertension mainly by an endothelium-dependent manner, probably due to NO release, and also through an endothelium-independent pathway by opening K+ channels. Tilianin inhibits the tumor necrotic factor-K (TNF-K)-induced expression of VCAM-1 by 74% and reduces TNF-K-induced activation of nuclear factor-UB in cultured human umbilical vein endothelial cells (HUVECs). |
| CFN98026 | Tiliroside Tiliroside possesses anti-inflammatory, antioxidant, anti-complement, anti-diabetic, anticarcinogenic and hepatoprotective activities. Tiliroside enhances fatty acid oxidation via the enhancement adiponectin signaling associated with the activation of both AMP-activated protein kinase and peroxisome proliferator-activated receptor α and ameliorates obesity-induced metabolic disorders. |
| CFN90779 | Timorsaponin C Reference standards. |
| CFN98151 | Timosaponin A3 Timosaponin A3 triggers liver injury through inducing ROS generation and suppressing the expression of BA transporters, it has selectively cytotoxic for cancer versus normal cells. Timosaponin A3 can inhibit nuclear factor-kB and p38 signaling in TNF-a stimulated BV2 microglia cells, it has the therapeutic potential for various neurodegenerative diseases caused by inflammation. Timosaponin A3 also has application for reducing blood sugar and treating type-B diabete. |
| CFN90917 | Timosaponin AI Timosaponin AI can inhibit dipeptidyl peptidase-4 (DPP-4) activity in a dose-dependent manner, the DPP-4 inhibitor has been clinically used for the treatment of type 2 diabetes mellitus. |
| CFN98150 | Timosaponin BII Timosaponin BII has anti-diabetes, antioxidant, anti-inflammatory, and anti-dementia activities, it can significantly reduce the neurotoxicity induced by beta amyloid peptide 25-35 in primary neurons, the mechanism of which may be related with resisting oxidative damage and regulating the cholinergic system.Timosaponin BII can improve the neurological symptoms of cerebral ischemic rat, reduce infarct size, relieve brain water edema, improve hemorheology, reduce inflammatory injury of cerebral ischemia; it could be used in the preparation of a medicament or product for the prevention and treatment of stroke. |
| CFN00142 | Tirandamycin B Tirandamycin B is a BmAsnRS inhibitor, it is a leading anti-filarial drug . Tirandamycin B has antitumor and antibacterial activities. |
